BridgeBio Pharma, Inc.
BBIO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BBIO
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering therapies for genetic diseases and cancers, with a lead commercial product Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM) and a pipeline spanning over 20 disease states.
Key risk: Clinical and regulatory risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$14.97B
Cash Runway
35.1 moLead Asset
attruby (Approved)
Next Catalyst
Phase3_Topline · May 15, 2028Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 5 clinical trials · 7 catalysts for BridgeBio Pharma, Inc..
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering therapies for genetic diseases and cancers, with a lead commercial product Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM) and a pipeline spanning over 20 disease states.
- BridgeBio has a commercial product, Attruby (acoramidis), approved for ATTR-CM, and has submitted an NDA for oral BBP-418 for LGMD2I/R9 [sec_mda · as of 2026-05-07].
- As of June 30, 2026, the company reported cash & equivalents of $680.0M, total revenue of $243.7M, shareholders' equity of -$1,787.9M, and total debt of $2,652.9M [sec].
- The company's pipeline includes programs for achondroplasia, limb-girdle muscular dystrophy type 2I/R9, and autosomal dominant hypocalcemia type 1, among others [sec · filed 2026-04-24].
- BridgeBio has historically financed operations through equity sales, convertible notes, debt, royalty monetization, and product revenue, but has incurred significant operating losses since inception [sec_mda · as of 2026-05-07].
- The company has an upcoming Phase 3 topline readout for acoramidis on May 15, 2028, and patent expiries for NULIBRY in 2029 and TRUSELTIQ in 2034 [catalyst_timeline].
What works
- BridgeBio's lead product Attruby (acoramidis) is approved for ATTR-CM, providing a commercial revenue stream and a foundation for further pipeline development [sec · filed 2026-01-12].
- The company has demonstrated efficient drug development, with an average investment of less than $40 million per program to proof-of-concept data and less than $10 million to IND submission [sec · filed 2026-04-24].
- Several pipeline programs target large market opportunities, with potential annual sales of at least $1.0 billion per indication if approved [sec · filed 2024-04-25].
What to weigh
- BridgeBio has a significant accumulated deficit and negative shareholders' equity of -$1,787.9M as of June 30, 2026, reflecting years of operating losses [sec].
- The company carries substantial debt of $2,652.9M as of June 30, 2026, including convertible notes and deferred royalty obligations, which creates financial leverage and repayment risk [sec].
- The company's ability to achieve profitability depends heavily on the successful development and commercialization of its product candidates, many of which are still in clinical stages [sec_mda · as of 2026-08-10].
- BridgeBio faces risks from clinical trial outcomes, regulatory approvals, and market adoption, with no guarantee that current or future product candidates will succeed [sec · filed 2026-01-12].
From the filings
Quoted directly from source documents.
BridgeBio has a commercial product Attruby and a pipeline of advanced candidates.
“In addition to our commercial products led by Attruby, we plan to pursue regulatory submissions for several advanced product candidates, including therapies for achondroplasia, limb-girdle muscular dystrophy type 2I/R9, and autosomal dominant hypocalcemia type 1”
SEC filings · April 24, 2026
BridgeBio has incurred significant operating losses since inception.
“Since inception, we have incurred significant operating losses.”
SEC MD&A · May 7, 2026
BridgeBio's pipeline targets large market opportunities.
“Several of our programs target indications that we believe present the potential for our product candidates, if approved, to target portions of market opportunities of at least $1.0 billion in annual sales.”
SEC filings · April 25, 2024
BridgeBio has an efficient drug development model.
“proof-of-concept with speed and efficiency, demonstrated by an average investment per program of less than $40.0 million to proof-of-concept data and less than $10.0 million to reach Investigational New Drug ("IND") submission.”
SEC filings · April 24, 2026
Catalyst timeline
- 2028-05-15 · Phase3_Topline · acoramidis — Topline results from an open-label extension and safety monitoring study of acoramidis in symptomatic ATTR-CM patients.
- 2029-04-09 · Patent_Expiry · NULIBRY — Patent or exclusivity expiry for NULIBRY, which could affect market protection.
- 2030-12-01 · Phase3_Topline — Phase 2/3 topline data from a multicenter, open-label study evaluating pharmacokinetics, efficacy, and safety.
- 2032-12-01 · Phase3_Topline · acoramidis — Phase 3 topline data from a randomized, placebo-controlled study of acoramidis for transthyretin amyloidosis.
- 2034-12-11 · Patent_Expiry · TRUSELTIQ — Patent or exclusivity expiry for TRUSELTIQ, potentially impacting revenue.
- 2037-12-01 · Phase3_Topline · acoramidis — Phase 3 topline data from an open-label, multicenter extension study of acoramidis in newly diagnosed patients.
- 2039-08-16 · Patent_Expiry · ATTRUBY — Patent or exclusivity expiry for ATTRUBY, which could affect long-term market exclusivity.
Risks & what to watch (4)›
Key risks
- Clinical and regulatory risk — Pipeline candidates may fail in clinical trials or face regulatory hurdles, impacting future revenue and viability [sec · filed 2026-01-12].
- High debt and negative equity — Total debt of $2,652.9M and negative equity of -$1,787.9M as of June 30, 2026, create financial strain and limit flexibility [sec].
- Dependence on commercial success — Profitability relies heavily on Attruby and future product sales, which may not materialize as expected [sec_mda · as of 2026-08-10].
- Contingent payment obligations — Milestone payments under license agreements could increase costs and reduce cash reserves [sec_mda · as of 2026-08-10].
What to watch
- Phase 3 topline data for acoramidis expected on May 15, 2028 [catalyst_timeline].
- Regulatory decisions on NDA for BBP-418 for LGMD2I/R9, submitted March 30, 2026 [sec_mda · as of 2026-05-07].
- Patent expiries for NULIBRY (2029) and TRUSELTIQ (2034) which could impact exclusivity [catalyst_timeline].
- Cash runway and ability to manage $2.65B debt load given ongoing operating losses [sec].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BridgeBio Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BridgeBio Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
35.1 months
OCF -$71M
Lead: Approved
3 candidates
7 upcoming, next in ~624d
0 buys · 75 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
460
Total value held
$15.04B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 26,358,026 | $1.96B |
| vanguard capital management llc | 15,518,990 | $1.15B |
| blackrock, inc. | 14,207,757 | $1.06B |
| viking global investors lp | 11,842,434 | $879.4M |
| farallon capital management llc | 9,365,463 | $695.5M |
| vanguard portfolio management llc | 8,080,573 | $600.1M |
| ubs group ag | 5,890,321 | $437.4M |
| geode capital management, llc | 4,918,030 | $371.9M |
| jane street group, llc | 4,935,272 | $366.5M |
| state street corp | 4,934,320 | $366.4M |
Showing top 10 of 460 institutional holders of BridgeBio Pharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 13.7%
- Days to cover
- 9.8
- Shares short
- 24,026,982
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BBIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for BridgeBio Pharma, Inc.?
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering therapies for genetic diseases and cancers, with a lead commercial product Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM) and a pipeline spanning over 20 disease states.
What is BridgeBio Pharma, Inc.'s lead drug candidate?
BridgeBio Pharma, Inc.'s most advanced tracked candidate is attruby (Approved) for Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
What is BridgeBio Pharma, Inc.'s next catalyst?
BridgeBio Pharma, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Sympto" — expected May 15, 2028.
Who is the CEO of BridgeBio Pharma, Inc.?
Dr. Neil Kumar Ph.D. is the chief executive officer of BridgeBio Pharma, Inc. (BBIO).
Where is BridgeBio Pharma, Inc. headquartered?
BridgeBio Pharma, Inc. (BBIO) is headquartered in Palo Alto, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.